May 20, 2021|

UCB Awarded as Top 10 Supply Chain Partner by JD.com

Share:

by Hui Zhang

Union Chimique Belge (UCB), a leading global biopharmaceutical company from Belgium, was rewarded by JD.com as one of its Top 10 Supply Chain Partners at a May 20 kick-off event for this year’s 618 Grand Promotion from June 1-18th.

UCB was rewarded along with other companies including P&G, Unilever, Li-Ning, and Chinese home appliances giant, Haier, etc.

The partnership which began in November 2019 takes advantage of JD’s strength in supply chain and e-commerce capabilities and UCB’s years of research and development focusing on treatments for severe diseases particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergies), and oncology. The two parties are also exploring how to help patients and make it easy for them to buy drugs at affordable prices online.

Representatives from P&G, Unilever, Li-Ning, Haier, Deli, JOMOO, Lam pure, winxuan.com, UCB China, and Zhenyun Technology receiving awards

In April, 2021, JD became the agent for UCB’s Cetirizine Dihydrochloride tablets for the treatment of allergies. With the agreement, JD Health will be working as an agent for a pharmaceutical company to undertake UCB’s online and offline pharmaceutical distribution businesses.

Last February, UCB joined JD Health’s platform to connect chronic patients with pharmaceutical companies and pharmacies and provide timely information on where they can get the drugs they need, online or offline.

Coping with rising demands from patients with epilepsy during the pandemic, UCB in partnership with JD Health also jointly launched an Epilepsy Service Center within JD’s app to provide expert knowledge through livestreaming, pictures, and tests, online consultations, and medical drugs. Patients can enjoy a one-stop services covering medical reviews, repeat prescriptions, drug purchasing and delivery. So far, the service center has gathered more than 500 epilepsy specialists (both adult and pediatric) from major hospitals across China.

“We will take our cooperation with UCB as a starting point to continue strengthening our service capability in pharmaceutical distribution and work with more pharmaceutical companies to enhance the accessibility of quality drugs,” said Enlin Jin, vice president of JD Health and general manager of the company’s medicine business.

“UCB will continue to serve as a bridge between China and Belgium to promote more exchanges and cooperation for the benefit of Chinese and global patients,” said Xin Wu, general manager of UCB China.

 

(zhanghui36@jd.com)

 

Share: